<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626795</url>
  </required_header>
  <id_info>
    <org_study_id>TD1414-C21</org_study_id>
    <nct_id>NCT00626795</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)</brief_title>
  <official_title>Efficacy, Safety and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An international, multi-centre, prospective three arm parallel-group, phase II proof of
      concept study comparing the efficacy and safety of two dosage regimens (BID 7 days and TID 7
      days) of TD1414 2% cream and one dosage regimen (BID 7 days) of Bactroban® (mupirocin) 2%
      cream in adults and children down to 2 years of age with impetigo or SITL. Furthermore an
      evaluation of the pharmacokinetics of TD1414 2% cream TID for 7 days will be performed. A
      total of 664 patients will be enrolled in a stepwise manner according to age groups starting
      with the oldest age group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Clinical Cure According to Investigator's Assessment</measure>
    <time_frame>At end of treatment (Day 8)</time_frame>
    <description>At end of treatment (Day 8), the participants had their impetigo/Secondarily Infected Traumatic Lesions (SITL) evaluated by the (sub)investigator.
Investigator's assessment of severity of infections (SIRS).
Exudates/pus
Crusting
Erythema
Oedema
Tissue Warmth
Itching
Pain
Each sign/symptoms of infection was assessed by use of the following 4-point scale:
0 = absent
2 = mild
4 = moderate
6 = severe
The scores were summed up to a total SIRS score.
Clinical cure was either of the following:
Total absence of signs and symptoms of impetigo/SITL OR
Improvement - total SIRS score reduced to &lt;8 and all individual clinical signs/symptoms included in the SIRS score should have been ≤4.
Clinical failure was either of the following:
Signs and symptoms of impetigo/SITL that did not meet the definition of clinical cure
Unable to determine (e.g. participants who refuse clinical examination or did not show at end of treatment or follow-up).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Clinical Cure According to Investigator's Assessment</measure>
    <time_frame>At follow up (Day 15)</time_frame>
    <description>At follow up (Day 15), the participants had their impetigo/SITL evaluated by the (sub)investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Clinical Cure According to Investigator's Assessment.</measure>
    <time_frame>At end of treatment (Day 8) and follow-up (Day 15)</time_frame>
    <description>At end of treatment (Day 8) and at follow-up (Day 15), the participants had their impetigo/SITL evaluated by the (sub)investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Bacteriological Cure According to Bacteriological Samples</measure>
    <time_frame>At end of treatment (Day 8), follow-up (Day 15) and end of treatment and follow-up</time_frame>
    <description>At baseline (Day 1), end of treatment (EOT), and follow-up (FU), the investigator obtained a bacteriological sample to base the assessment on.
Bacteriological cure was either of the following:
Eradication of the baseline pathogen.
Presumed eradication of the baseline pathogen
Infection with a pathogen different from the baseline pathogen at EOT or FU and the participant was NOT symptomatic.
Bacteriological failure was any of the following:
Documented lack of eradication of the baseline pathogen.
Documented relapse (re-infection) with the baseline pathogen
Documented super-infection, i.e. infection with a pathogen different from the baseline pathogen at EOT or FU, and the participants was symptomatic
Presumed persistence of baseline pathogen: Non-evaluable participants- participants who refused bacteriological examination or did not show at EOT or FU, and clinical failures who had no bacteriological sample to rule out bacterial infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Clinical and Bacteriological Cure According to Investigator's Assessment and Bacteriological Samples</measure>
    <time_frame>At end of treatment (Day 8), follow-up (Day 15) and end of treatment and follow-up</time_frame>
    <description>At end of treatment (Day 8) and at follow-up (Day 15) the participants had their impetigo/SITL evaluated by the (sub)investigator.
At baseline (Day 1), end of treatment (Day 8) and at follow-up (Day 15) the investigator obtained a bacteriological sample on which an assessment of bacteriological cure was based.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Clinical Cure According to Investigator's Assessment</measure>
    <time_frame>At Day 4</time_frame>
    <description>At Day 4 the participants had their impetigo/SITL evaluated by the (sub)investigator.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">773</enrollment>
  <condition>Impetigo</condition>
  <condition>Secondarily Infected Traumatic Lesions</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD1414 2% cream</intervention_name>
    <description>BID 7 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD1414 2% cream</intervention_name>
    <description>TID 7 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bactroban® (mupirocin) 2% cream</intervention_name>
    <description>BID 7 days</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent from patient and/or legally acceptable
             representative has been obtained

          -  Outpatients of any sex or ethnic origin

          -  Patients &gt;= 2 years of age (depending on study step)

          -  Patients must be suffering from primary bullous/non-bullous impetigo or SITL

        Exclusion Criteria:

          -  Presence of skin diseases at or near the investigational area

          -  Immunosuppressed state or other serious systemic disease

          -  Signs and/or symptoms of systemic infection

          -  Presence of skin infection/disorder not amenable to topical antibacterial treatment
             only

          -  Presence of secondarily-infected animal/human bite

          -  Presence of secondarily infected burnwound

          -  Topical or systemic use of medicinal or other products before or during the study
             which in the investigators opinion could confound the evaluation of the effect of the
             study drugs

          -  Known or suspected hypersensitivity to TD1414 or any of the excipients in the TD1414
             2% cream

          -  Known or suspected hypersensitivity to mupirocin or any of the excipients in the
             Bactroban® (mupirocin) 2% cream

          -  Participation in any other investigational drug study or use of (an) investigational
             drug(s) within the 30 days or 5 half-lives (whichever is longer) prior to
             randomisation

          -  Patients previously enrolled/randomised in this study

          -  Abnormal ECG at baseline though the PR interval may be up to 220 ms, the QRS interval
             up to 110 ms and the QTc interval up to 450 ms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Almena L Free, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anniston Medical Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anniston Medical Clinic</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Dermatology, Groote Schuur Hospital, G23</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 21, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <results_first_submitted>June 26, 2018</results_first_submitted>
  <results_first_submitted_qc>June 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2018</results_first_posted>
  <last_update_submitted>August 10, 2018</last_update_submitted>
  <last_update_submitted_qc>August 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Impetigo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mupirocin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>An open-label treatment consisting of one arm with 4 age groups of 16 participants treated with TD1414 cream three times daily was used in a stepwise inclusion, to detect major safety issues that could prevent the study from proceeding. The participants in the open-label phase were not included the efficacy analysis or in the randomized population</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TD1414 BID</title>
          <description>TD1414 2% cream: two times daily (BID) 7 days</description>
        </group>
        <group group_id="P2">
          <title>TD1414 TID</title>
          <description>TD1414 2% cream: three times daily (TID) 7 days</description>
        </group>
        <group group_id="P3">
          <title>Bactroban® TID</title>
          <description>Bactroban® (mupirocin) 2% cream: three times daily (TID) 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-label TD1414 Cream TID Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Blinded Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="205"/>
                <participants group_id="P3" count="205"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="200"/>
                <participants group_id="P3" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unacceptable adverse event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing reason for withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TD1414 BID</title>
          <description>TD1414 2% cream: two times daily (BID) 7 days</description>
        </group>
        <group group_id="B2">
          <title>TD1414 TID</title>
          <description>TD1414 2% cream: three times daily (TID) 7 days</description>
        </group>
        <group group_id="B3">
          <title>Bactroban® TID</title>
          <description>Bactroban® (mupirocin) 2% cream: three times daily (TID) 7 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="204"/>
            <count group_id="B2" value="205"/>
            <count group_id="B3" value="205"/>
            <count group_id="B4" value="614"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>65 participants were assigned to open-label TD1414 cream TID treatment for the purpose of safety evaluations.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Participants assigned to open-label TD1414 TID</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="65"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="18.4" spread="20.0"/>
                    <measurement group_id="B4" value="18.4" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants randomized to blinded treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="205"/>
                    <count group_id="B4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.6" spread="14.8"/>
                    <measurement group_id="B2" value="36.3" spread="14.3"/>
                    <measurement group_id="B3" value="38.3" spread="15.3"/>
                    <measurement group_id="B4" value="37.7" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <population>65 participants were assigned to open-label TD1414 cream TID treatment for the purpose of safety evaluations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Participants assigned to open-label TD1414 TID</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="65"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>≥16 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥12 to &lt;16 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥6 to &lt;12 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2 to &lt;6 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants randomized to blinded treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="205"/>
                    <count group_id="B4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>≥16 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="195"/>
                    <measurement group_id="B4" value="582"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥12 to &lt;16 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥6 to &lt;12 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥2 to &lt;6 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>65 participants were assigned to open-label TD1414 cream TID treatment for the purpose of safety evaluations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Participants assigned to open-label TD1414 TID</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="65"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants randomized to blinded treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="205"/>
                    <count group_id="B4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="205"/>
                    <count group_id="B4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="204"/>
                    <count group_id="B2" value="205"/>
                    <count group_id="B3" value="205"/>
                    <count group_id="B4" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Clinical Cure According to Investigator's Assessment</title>
        <description>At end of treatment (Day 8), the participants had their impetigo/Secondarily Infected Traumatic Lesions (SITL) evaluated by the (sub)investigator.
Investigator's assessment of severity of infections (SIRS).
Exudates/pus
Crusting
Erythema
Oedema
Tissue Warmth
Itching
Pain
Each sign/symptoms of infection was assessed by use of the following 4-point scale:
0 = absent
2 = mild
4 = moderate
6 = severe
The scores were summed up to a total SIRS score.
Clinical cure was either of the following:
Total absence of signs and symptoms of impetigo/SITL OR
Improvement - total SIRS score reduced to &lt;8 and all individual clinical signs/symptoms included in the SIRS score should have been ≤4.
Clinical failure was either of the following:
Signs and symptoms of impetigo/SITL that did not meet the definition of clinical cure
Unable to determine (e.g. participants who refuse clinical examination or did not show at end of treatment or follow-up).</description>
        <time_frame>At end of treatment (Day 8)</time_frame>
        <population>All participants randomized to blinded treatment who received at least one application of study medication were included in the efficacy analysis. Two participants (one from TD1414 BID and one from Bactroban® TID) did not receive any study medication and are therefore not included.</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414 BID</title>
            <description>TD1414 2% cream: two times daily (BID) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>TD1414 TID</title>
            <description>TD1414 2% cream: three times daily (TID) for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Bactroban® TID</title>
            <description>Bactroban® (mupirocin) 2% cream: three times daily (TID) for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Clinical Cure According to Investigator's Assessment</title>
          <description>At end of treatment (Day 8), the participants had their impetigo/Secondarily Infected Traumatic Lesions (SITL) evaluated by the (sub)investigator.
Investigator's assessment of severity of infections (SIRS).
Exudates/pus
Crusting
Erythema
Oedema
Tissue Warmth
Itching
Pain
Each sign/symptoms of infection was assessed by use of the following 4-point scale:
0 = absent
2 = mild
4 = moderate
6 = severe
The scores were summed up to a total SIRS score.
Clinical cure was either of the following:
Total absence of signs and symptoms of impetigo/SITL OR
Improvement - total SIRS score reduced to &lt;8 and all individual clinical signs/symptoms included in the SIRS score should have been ≤4.
Clinical failure was either of the following:
Signs and symptoms of impetigo/SITL that did not meet the definition of clinical cure
Unable to determine (e.g. participants who refuse clinical examination or did not show at end of treatment or follow-up).</description>
          <population>All participants randomized to blinded treatment who received at least one application of study medication were included in the efficacy analysis. Two participants (one from TD1414 BID and one from Bactroban® TID) did not receive any study medication and are therefore not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Clinical cure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="184"/>
                    <measurement group_id="O3" value="174"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clinical failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The lower confidence limit greater or equal to -12.5% indicates non-inferiority.</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>4.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.59</ci_lower_limit>
            <ci_upper_limit>10.71</ci_upper_limit>
            <estimate_desc>Estimated using a Cochran-Mantel-Haenszel approach, stratifying by country and disease (impetigo/SITL).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The lower confidence limit greater or equal to -12.5% indicates non-inferiority.</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>-3.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.28</ci_lower_limit>
            <ci_upper_limit>3.57</ci_upper_limit>
            <estimate_desc>Estimated using a Cochran-Mantel-Haenszel approach, stratifying by country and disease (impetigo/SITL).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Clinical Cure According to Investigator's Assessment</title>
        <description>At follow up (Day 15), the participants had their impetigo/SITL evaluated by the (sub)investigator.</description>
        <time_frame>At follow up (Day 15)</time_frame>
        <population>All participants randomized to blinded treatment who received at least one application of study medication were included in the efficacy analysis. Two participants (one from TD1414 BID and one from Bactroban® TID) did not receive any study medication and are therefore not included.</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414 BID</title>
            <description>TD1414 2% cream: two times daily (BID) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>TD1414 TID</title>
            <description>TD1414 2% cream: three times daily (TID) for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Bactroban® TID</title>
            <description>Bactroban® (mupirocin) 2% cream: three times daily (TID) for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Clinical Cure According to Investigator's Assessment</title>
          <description>At follow up (Day 15), the participants had their impetigo/SITL evaluated by the (sub)investigator.</description>
          <population>All participants randomized to blinded treatment who received at least one application of study medication were included in the efficacy analysis. Two participants (one from TD1414 BID and one from Bactroban® TID) did not receive any study medication and are therefore not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Clinical cure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="188"/>
                    <measurement group_id="O3" value="185"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clinical failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Clinical Cure According to Investigator's Assessment.</title>
        <description>At end of treatment (Day 8) and at follow-up (Day 15), the participants had their impetigo/SITL evaluated by the (sub)investigator.</description>
        <time_frame>At end of treatment (Day 8) and follow-up (Day 15)</time_frame>
        <population>All participants randomized to blinded treatment who received at least one application of study medication were included in the efficacy analysis. Two participants (one from TD1414 BID and one from Bactroban® TID) did not receive any study medication and are therefore not included.</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414 BID</title>
            <description>TD1414 2% cream: two times daily (BID) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>TD1414 TID</title>
            <description>TD1414 2% cream: three times daily (TID) for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Bactroban® TID</title>
            <description>Bactroban® (mupirocin) 2% cream: three times daily (TID) for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Clinical Cure According to Investigator's Assessment.</title>
          <description>At end of treatment (Day 8) and at follow-up (Day 15), the participants had their impetigo/SITL evaluated by the (sub)investigator.</description>
          <population>All participants randomized to blinded treatment who received at least one application of study medication were included in the efficacy analysis. Two participants (one from TD1414 BID and one from Bactroban® TID) did not receive any study medication and are therefore not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="177"/>
                    <measurement group_id="O3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Bacteriological Cure According to Bacteriological Samples</title>
        <description>At baseline (Day 1), end of treatment (EOT), and follow-up (FU), the investigator obtained a bacteriological sample to base the assessment on.
Bacteriological cure was either of the following:
Eradication of the baseline pathogen.
Presumed eradication of the baseline pathogen
Infection with a pathogen different from the baseline pathogen at EOT or FU and the participant was NOT symptomatic.
Bacteriological failure was any of the following:
Documented lack of eradication of the baseline pathogen.
Documented relapse (re-infection) with the baseline pathogen
Documented super-infection, i.e. infection with a pathogen different from the baseline pathogen at EOT or FU, and the participants was symptomatic
Presumed persistence of baseline pathogen: Non-evaluable participants- participants who refused bacteriological examination or did not show at EOT or FU, and clinical failures who had no bacteriological sample to rule out bacterial infection.</description>
        <time_frame>At end of treatment (Day 8), follow-up (Day 15) and end of treatment and follow-up</time_frame>
        <population>Only the randomized participants that were infected with S. aureus or S. pyogenes at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414 BID</title>
            <description>TD1414 2% cream: two times daily (BID) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>TD1414 TID</title>
            <description>TD1414 2% cream: three times daily (TID) for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Bactroban® TID</title>
            <description>Bactroban® (mupirocin) 2% cream: three times daily (TID) for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Bacteriological Cure According to Bacteriological Samples</title>
          <description>At baseline (Day 1), end of treatment (EOT), and follow-up (FU), the investigator obtained a bacteriological sample to base the assessment on.
Bacteriological cure was either of the following:
Eradication of the baseline pathogen.
Presumed eradication of the baseline pathogen
Infection with a pathogen different from the baseline pathogen at EOT or FU and the participant was NOT symptomatic.
Bacteriological failure was any of the following:
Documented lack of eradication of the baseline pathogen.
Documented relapse (re-infection) with the baseline pathogen
Documented super-infection, i.e. infection with a pathogen different from the baseline pathogen at EOT or FU, and the participants was symptomatic
Presumed persistence of baseline pathogen: Non-evaluable participants- participants who refused bacteriological examination or did not show at EOT or FU, and clinical failures who had no bacteriological sample to rule out bacterial infection.</description>
          <population>Only the randomized participants that were infected with S. aureus or S. pyogenes at baseline were included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of treatment (Day 8)</title>
              <category_list>
                <category>
                  <title>Bacteriological cure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bacteriological failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (Day 15)</title>
              <category_list>
                <category>
                  <title>Bacteriological cure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bacteriological failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment and follow-up</title>
              <category_list>
                <category>
                  <title>Bacteriological cure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bacteriological failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Clinical and Bacteriological Cure According to Investigator's Assessment and Bacteriological Samples</title>
        <description>At end of treatment (Day 8) and at follow-up (Day 15) the participants had their impetigo/SITL evaluated by the (sub)investigator.
At baseline (Day 1), end of treatment (Day 8) and at follow-up (Day 15) the investigator obtained a bacteriological sample on which an assessment of bacteriological cure was based.</description>
        <time_frame>At end of treatment (Day 8), follow-up (Day 15) and end of treatment and follow-up</time_frame>
        <population>All participants randomized to blinded treatment who received at least one application of study medication and were infected with S. aureus or S. pyogenes at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414 BID</title>
            <description>TD1414 2% cream: two times daily (BID) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>TD1414 TID</title>
            <description>TD1414 2% cream: three times daily (TID) for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Bactroban® TID</title>
            <description>Bactroban® (mupirocin) 2% cream: three times daily (TID) for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Clinical and Bacteriological Cure According to Investigator's Assessment and Bacteriological Samples</title>
          <description>At end of treatment (Day 8) and at follow-up (Day 15) the participants had their impetigo/SITL evaluated by the (sub)investigator.
At baseline (Day 1), end of treatment (Day 8) and at follow-up (Day 15) the investigator obtained a bacteriological sample on which an assessment of bacteriological cure was based.</description>
          <population>All participants randomized to blinded treatment who received at least one application of study medication and were infected with S. aureus or S. pyogenes at baseline were included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of treatment (Day 8)</title>
              <category_list>
                <category>
                  <title>Clinical and bacteriological cure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clinical or bacteriological failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up (Day 15)</title>
              <category_list>
                <category>
                  <title>Clinical and bacteriological cure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clinical or bacteriological failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment and follow-up</title>
              <category_list>
                <category>
                  <title>Clinical and bacteriological cure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clinical or bacteriological failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Clinical Cure According to Investigator's Assessment</title>
        <description>At Day 4 the participants had their impetigo/SITL evaluated by the (sub)investigator.</description>
        <time_frame>At Day 4</time_frame>
        <population>All participants randomized to blinded treatment who received at least one application of study medication were included in the efficacy analysis. Two participants (one from TD1414 BID and one from Bactroban® TID) did not receive any study medication and are therefore not included.</population>
        <group_list>
          <group group_id="O1">
            <title>TD1414 BID</title>
            <description>TD1414 2% cream: two times daily (BID) for 7 days</description>
          </group>
          <group group_id="O2">
            <title>TD1414 TID</title>
            <description>TD1414 2% cream: three times daily (TID) for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Bactroban® TID</title>
            <description>Bactroban® (mupirocin) 2% cream: three times daily (TID) for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Clinical Cure According to Investigator's Assessment</title>
          <description>At Day 4 the participants had their impetigo/SITL evaluated by the (sub)investigator.</description>
          <population>All participants randomized to blinded treatment who received at least one application of study medication were included in the efficacy analysis. Two participants (one from TD1414 BID and one from Bactroban® TID) did not receive any study medication and are therefore not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Clinical cure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clinical failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day 4 to Follow-up (Day 15) and Additional Follow-up (Day 14 after follow-up)</time_frame>
      <desc>All patients assigned to open-label treatment who received at least one application of the study medication (TD1414) and for whom the presence or confirmed absence of adverse events was available were included in the open-label analysis set. All participants randomized to blinded treatment who received at least one application of study medication and for whom the presence or confirmed absence of adverse events was available were included in the safety analysis set and analyzed for safety.</desc>
      <group_list>
        <group group_id="E1">
          <title>TD1414 TID &gt;=16 Years</title>
          <description>Open-label phase TD1414 2% cream: three times daily (TID) for 7 days</description>
        </group>
        <group group_id="E2">
          <title>TD1414 TID &gt;=12 to &lt;16 Years</title>
          <description>Open-label phase TD1414 2% cream: three times daily (TID) for 7 days</description>
        </group>
        <group group_id="E3">
          <title>TD1414 TID &gt;=6 to &lt;12 Years</title>
          <description>Open-label phase TD1414 2% cream: three times daily (TID) for 7 days</description>
        </group>
        <group group_id="E4">
          <title>TD1414 TID &gt;=2 to &lt;6 Years</title>
          <description>Open-label phase TD1414 2% cream: three times daily (TID) for 7 days</description>
        </group>
        <group group_id="E5">
          <title>TD1414 BID</title>
          <description>Blinded treatment TD1414 2% cream: two times daily (BID) for 7 days</description>
        </group>
        <group group_id="E6">
          <title>TD1414 TID</title>
          <description>Blinded treatment TD1414 2% cream: three times daily (TID) for 7 days</description>
        </group>
        <group group_id="E7">
          <title>Bactroban® TID</title>
          <description>Blinded treatment Bactroban® (mupirocin) 2% cream: three times daily (TID) for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Penetrating abdominal trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Shunt occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="61" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="49" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="34" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Aneamia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lymphocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Long QT syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Treatment failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Application site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Human bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ligament disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Joint contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Tonsillar inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Company acknowledges the investigators’ right to publish the entire results of the study, irrespective of outcome. The Company retains the right to have any publication submitted to the Company for review at least 30 days prior to the same paper being submit-ted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 4494 5888</phone>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

